RBC Capital Downgrades Design Therapeutics Inc (DSGN) to Sector Perform 'pending further derisking'
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/28/2026
Go back to RBC Capital Downgrades Design Therapeutics Inc (DSGN) to Sector Perform 'pending further derisking'
August 15, 2023 6:02 AM EDT
SVB MoffettNathanson analyst Joseph Schwartz downgraded Design Therapeutics Inc (NASDAQ: DSGN) from Outperform to Market Perform with a price target of $6.00 (from $22.00).
For an analyst ratings summary and ratings history on Design Therapeutics Inc... More
August 14, 2023 4:01 PM EDT
Design Therapeutics, Inc. (Nasdaq: DSGN), a clinical-stage biotechnology company developing treatments for serious degenerative genetic diseases, today reported initial results from the companys Phase 1 multiple-ascending dose (MAD) clinical trial of DT-216 in patients with Friedrich ataxia (FA). As of a data cutoff date of August 7, 2023, results showed that DT-216 was generally well-tolerated and achieved a statistically significant and dose-related increase in frataxin (FXN) mRNA levels in skeletal muscle biopsies.
FA is a multisystem degenerative disease caused by a GAA nucleotide repeat expansion in the FXN gene that impairs transcription and reduces FXN... More
